Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to: - Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients - Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting - Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04561518
Study type Observational
Source Alnylam Pharmaceuticals
Contact Alnylam Clinical Trial Information Line
Phone 1-877-ALNYLAM
Status Recruiting
Start date November 23, 2020
Completion date September 2030

See also
  Status Clinical Trial Phase
Completed NCT02595983 - The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant Phase 2
Recruiting NCT05444920 - The Italian Transthyretin Amyloidosis Web-Network
Recruiting NCT05184088 - Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis Phase 3
Recruiting NCT06367842 - Orthopaedic Specimen Pathology and Early Diagnosis of ATTR Cardiopathy (ATTR-ORTHO)
Recruiting NCT06355934 - OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis